SNSS Sunesis Pharmaceuticals

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Sunesis Pharmaceuticals Inc.

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky, LLP announces it has commenced an investigation of Sunesis Pharmaceuticals Inc. (“Sunesis”) (NASDAQ: SNSS) concerning possible violations of federal securities laws.

The investigation concerns whether the Company and its executives violated federal securities laws by failing to appropriately disclose the suitability of the Company's treatment vosaroxin for approval in Europe. Specifically, on May 2, 2017, Sunesis announced that the Company will withdraw its European Marketing Authorization Application for vosaroxin, following recent interactions with the European Medicine Agency's Committee for Medicinal Products for Human Use. Sunesis announced that it had learned that the committee was likely to formally adopt a negative opinion in its evaluation of the product, leading to its withdrawal. To obtain additional information, go to:

http://zlk.9nl.com/sunesis-snss

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
03/05/2017

Underlying

SNSSSunesis Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sunesis Pharmaceuticals

Sean Conroy
  • Sean Conroy
SNSS Sunesis Pharmac...

Sunesis Pharmaceuticals - A shift of gears

Sunesis’s task in realigning the company towards its new lead asset SNS-510 is twofold. First, it is examining the precise direction it intends to take the drug, and it has found synergies both with certain genetic subtypes of cancer as well as with other cancer drugs. Secondly, the company is both raising capital and reducing costs in order to provide the drug a runway into the clinic, and it estimates that it has cash through most of 2021.

SNSS SUNESIS PHARMACEUTICALS
08/20/20 August 20, 2020 5 EN
Sean Conroy
  • Sean Conroy
SNSS Sunesis Pharmac...

Sunesis Pharmaceuticals - Vecabrutinib not to progress, SNS-510 elevat...

Sunesis announced on 23 June that it would not be advancing vecabrutinib to the Phase II portion of its Phase Ib/II study following the results from its highest dose (500mg) cohort. The cohort had three stable disease (SD) responses out of six patients enrolled in the cohort, and Sunesis determined that this level of activity was not sufficient to warrant advancing the program. The company will now refocus efforts on developing its PDK1 inhibitor SNS-510, for which it expects to file an IND by t...

SNSS SUNESIS PHARMACEUTICALS
06/26/20 June 26, 2020 5 EN
Free Trial
SNSS Sunesis Pharmac...

Thanks to a better fundamental star rating, SUNESIS PHARMS.INCO. sees ...

The independent financial analyst theScreener just awarded an improved star rating to SUNESIS PHARMS.INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 4 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date June 9, 2020, the closin...

SNSS SUNESIS PHARMACEUTICALS
06/10/20 June 10, 2020 6 EN
Sean Conroy
  • Sean Conroy
SNSS Sunesis Pharmac...

Sunesis Pharmaceuticals - 400mg data similar to previous cohort

On 18 March, Sunesis released the first assessments of the 400mg cohort in its ongoing dosing study of vecabrutinib for B-cell malignancies. Two (of three) patients in this cohort showed stable disease (SD), with one showing a 48% response. These results are largely similar to those seen with the 300mg cohort (one near-responder SD, two stabilized SD, and one progressor). We would like to have seen more definitive activity in this cohort, but there is still the possibility that Sunesis will cros...

SNSS SUNESIS PHARMACEUTICALS
03/26/20 March 26, 2020 6 EN
Sean Conroy
  • Sean Conroy
SNSS Sunesis Pharmac...

Sunesis Pharmaceuticals - Sunesis 110320

Sunesis provided an update on its ongoing dosing study of vecabrutinib on its 2019 earning conference call: the first response assessment for the 400mg cohort will be available later in March and the 500mg readout should be available in Q220. Sunesis noted one patient on the 300mg arm is on his eighth line of treatment and his response has developed to a 47% response (from 41% at the last update), just shy of a partial response (PR).

SNSS SUNESIS PHARMACEUTICALS
03/12/20 March 12, 2020 5 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch